Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23361203 | 1.00 | POLB (0.50) | POLBTDP1AGTR2OPRM1OPRD1 | |
| SCHEMBL19748551 | 0.94 | POLB (0.50) | POLBTDP1AGTR2ACEHSD17B3 | |
| SCHEMBL28808110 | 0.85 | POLB (0.48) | POLBTDP1OPRM1OPRD1OPRK1 | |
| SCHEMBL28947406 | 0.85 | POLB (0.48) | POLBTDP1OPRM1OPRD1OPRK1 | |
| SCHEMBL20522865 | 0.83 | OPRD1 (0.57) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL20522864 | 0.83 | OPRD1 (0.57) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL17433720 | 0.83 | OPRD1 (0.57) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL31362395 | 0.83 | PTPN1 (0.53) | POLBTDP1 | |
| SCHEMBL20720152 | 0.82 | OPRD1 (0.47) | POLBTDP1AGTR2OPRM1OPRD1 | |
| SCHEMBL7156807 | 0.82 | OPRD1 (0.47) | POLBTDP1AGTR2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | claimed |
| US-20230002375-A1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021094301-A1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-20 | — | — | WO | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002375-A1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, HLA-DRB1, HRH2 | POLB 500/4885TDP1 2228/4885AGTR2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.